Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.47 |
| ▸ | APOB | P04114 | 2/20 | 0.46 |
| ▸ | MTTP | P55157 | 2/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160923 | 0.89 | TRPV1 (0.48) | KMT2AL3MBTL1TRPV1KDR | |
| SCHEMBL6799294 | 0.85 | KMT2A (0.56) | KMT2ATRPV1KDRSMOAPOB | |
| SCHEMBL6794977 | 0.85 | KDR (0.47) | TRPV1KDRSMOBDKRB1APOB | |
| SCHEMBL6795709 | 0.83 | MEN1 (0.59) | KMT2AL3MBTL1SMOAPOBMTTP | |
| SCHEMBL6913405 | 0.82 | MEN1 (0.59) | KMT2AAPOBMTTPKDM4E | |
| SCHEMBL6794043 | 0.81 | SMO (0.61) | KMT2AL3MBTL1TRPV1KDRSMO | |
| SCHEMBL6793184 | 0.81 | KMT2A (0.58) | KMT2AAPOBMTTPKDM4E | |
| SCHEMBL6792294 | 0.81 | FFAR2 (0.49) | TRPV1KDRSMOAPOBMTTP | |
| SCHEMBL6792281 | 0.80 | SMO (0.62) | TRPV1KDRSMOAPOBMTTP | |
| SCHEMBL6798808 | 0.79 | KDR (0.56) | KDRSMOAPOBMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | KMT2A 2457/4885L3MBTL1 1793/4885TRPV1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.